Insider Selling: Sionna Therapeutics (NASDAQ:SION) Director Sells $10,528,924.32 in Stock

Sionna Therapeutics, Inc. (NASDAQ:SION) Director Orbimed Advisors Llc sold 235,863 shares of the firm’s stock in a transaction on Wednesday, April 15th. The stock was sold at an average price of $44.64, for a total transaction of $10,528,924.32. Following the transaction, the director directly owned 3,247,025 shares of the company’s stock, valued at approximately $144,947,196. This represents a 6.77% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Orbimed Advisors Llc also recently made the following trade(s):

• On Thursday, April 16th, Orbimed Advisors Llc sold 226,906 shares of Sionna Therapeutics stock. The stock was sold at an average price of $45.34, for a total transaction of $10,287,918.04.
• On Tuesday, April 14th, Orbimed Advisors Llc sold 47,814 shares of Sionna Therapeutics stock. The stock was sold at an average price of $44.51, for a total transaction of $2,128,201.14.
• On Tuesday, February 3rd, Orbimed Advisors Llc sold 29,063 shares of Sionna Therapeutics stock. The stock was sold at an average price of $44.58, for a total transaction of $1,295,628.54.
• On Monday, February 2nd, Orbimed Advisors Llc sold 1,890 shares of Sionna Therapeutics stock. The stock was sold at an average price of $44.57, for a total transaction of $84,237.30.

Sionna Therapeutics Price Performance

Shares of SION stock opened at $43.54 on Friday. The firm has a market cap of $1.96 billion, a P/E ratio of -22.33 and a beta of 3.01. Sionna Therapeutics, Inc. has a 1-year low of $10.07 and a 1-year high of $46.46. The firm has a fifty day moving average of $37.74 and a two-hundred day moving average of $38.39.

Sionna Therapeutics (NASDAQ:SION) last posted its quarterly earnings results on Monday, March 2nd. The company reported ($0.46) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.61) by $0.15.

Analysts Set New Price Targets

Several research analysts have recently commented on SION shares. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Sionna Therapeutics in a report on Monday, December 29th. Raymond James Financial reaffirmed a “strong-buy” rating and issued a $53.00 price target on shares of Sionna Therapeutics in a report on Monday, January 5th. Citigroup started coverage on shares of Sionna Therapeutics in a report on Tuesday, February 24th. They issued an “outperform” rating for the company. Citizens Jmp started coverage on shares of Sionna Therapeutics in a report on Tuesday, February 24th. They issued a “market outperform” rating and a $63.00 price target for the company. Finally, Guggenheim lifted their price target on shares of Sionna Therapeutics from $45.00 to $50.00 and gave the company a “buy” rating in a report on Monday, March 2nd. Two investment analysts have rated the stock with a Strong Buy rating, six have issued a Buy rating and two have given a Sell rating to the stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $50.57.

Institutional Trading of Sionna Therapeutics

Hedge funds have recently bought and sold shares of the company. GF Fund Management CO. LTD. bought a new stake in Sionna Therapeutics in the 4th quarter valued at about $36,000. Russell Investments Group Ltd. bought a new stake in Sionna Therapeutics in the 3rd quarter valued at about $30,000. Balyasny Asset Management L.P. bought a new stake in Sionna Therapeutics in the 4th quarter valued at about $58,000. BNP Paribas Financial Markets bought a new stake in Sionna Therapeutics in the 2nd quarter valued at about $31,000. Finally, Mirae Asset Global Investments Co. Ltd. bought a new stake in Sionna Therapeutics in the 4th quarter valued at about $89,000.

Sionna Therapeutics News Summary

Here are the key news stories impacting Sionna Therapeutics this week:

• Positive Sentiment: The company reported an EPS beat on March 2 (reported -$0.46 vs. consensus -$0.61), a fundamental datapoint that supports investor sentiment and helps explain why the stock has traded above its 50/200‑day averages.
• Positive Sentiment: Despite selling, the reporting director (Orbimed / Peter A. Thompson) still holds a very large stake (roughly 3.0–3.5M shares), which tempers the interpretation that insiders are deserting the company.
• Neutral Sentiment: Many of the reported sales were executed under pre‑arranged Rule 10b5‑1 plans, which reduces the likelihood the trades reflect new negative private information.
• Neutral Sentiment: Analyst coverage is skewed positive: multiple buy/strong‑buy ratings and an average target (~$50.6) provide a supportive backdrop for sentiment.
• Negative Sentiment: Large, consecutive insider sell filings on April 14–16 total roughly 510K shares (~$22–23M at reported prices). That scale of director selling can create short‑term downward pressure and trigger investor concern despite 10b5‑1 protections. InsiderTrades Alert SEC Filing

About Sionna Therapeutics

Sionna Therapeutics is a clinical-stage biotechnology company dedicated to developing next-generation RNA therapeutics for oncology and immunology indications. Leveraging proprietary lipid nanoparticle and coacervate delivery technologies, the company aims to overcome key challenges associated with stability, targeting and immune activation that have historically limited the clinical performance of mRNA-based medicines. Its strategic focus spans both solid tumors and hematological malignancies, as well as selected autoimmune disorders, reflecting a broad ambition to harness the power of messenger RNA in diverse therapeutic areas.

At the heart of Sionna’s approach is a platform that combines optimized ionizable lipids with bespoke surface chemistries to enhance payload delivery, intracellular release and endosomal escape.